AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.

AstraZeneca's experimental cancer drug shows no significant improvement in overall survival

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Topline results from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to investigator's choice of chemotherapy, which previously met the dual primary endpoint of progression-free survival (PFS), did not achieve statistical significance in the final overall survival (OS) analysis in patients with inoperable or metastatic hormone receptor (HR) positive, HER2 low or negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer p.

Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

The latest trading day saw Astrazeneca (AZN) settling at $78.38, representing a -0.66% change from its previous close.

Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for self-administration, making it the first of its kind that patients can give themselves.

US FDA approves AstraZeneca's flu vaccine for self-administration

SPDR S&P 500 ETF Trust

Smurfit WestRock PLC

Billionaire investor George Soros became nearly a household name in the early 1990's by shorting the British pound and making $1 billion on the deal. His currency speculation earned him the moniker, “the man who broke the Bank of England.”

George Soros $4 Billion Hedge Fund Can't Stop Buying These 3 Stocks

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Bulls Look Optimistic About Astrazeneca (AZN): Should You Buy?

AbbVie

AstraZeneca and AbbVie outperformed the benchmark S&P 500 index over the past three-year, five-year, and 10-year periods. AbbVie offers a relatively high yield due to declining sales of its former lead drug Humira.

2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again

The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for the drug.

AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal.2,3 The approval by the US Food and Drug Administration (FDA) was based on positive results from the MANDARA Phase III trial published in The New England Journal of Medicine,4 w.

FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis

AstraZeneca PLC (NASDAQ:AZN ) Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ET Company Participants Pascal Soriot - Chief Executive Officer Susan Galbraith - EVP, Oncology R&D Thomas Powles - Professor of Genitourinary Oncology; Director, Barts Cancer Centre Sunil Verma - SVP, Global Head, Oncology Franchise Dave Fredrickson - EVP, Oncology Business Matt Hellmann - VP, Early Oncology Development Cristian Massacesi - Chief Medical Officer, Chief Development Officer Oncology Melissa Scaltrisi - Head of Traditional Medicine Leora Horn - Global Clinical Strategy Head for Lung Conference Call Participants Tony Ryan - Macquarie Emily Field - Barclays Christopher Uhde – SEB Simon Baker - Redburn Sam Fazeli - Bloomberg Intelligence Alana Lelo - Guggenheim Richard Parks - BNP Paribas Exane Andrew Berens - Leerink Partners Etzer Darout - BMO Capital Markets Gonzalo Artiach - Danske Bank Mattias Haggblom - Handelsbanken James Gordon - JPMorgan Luisa Hector - Berenberg Rajan Sharma - Goldman Sachs Operator Welcome, ladies and gentlemen, to AstraZeneca's Investor Conference Call ESMO 2024. Before I hand over to AstraZeneca's management team, I'd like to read the safe harbor statement.

AstraZeneca PLC (AZN) Meet the Management at ESMO 2024 Conference (Transcript)

Albertsons Companies

Dow Inc

Tesla

Walgreens

Investors like to think of themselves as rational and unattached. Still, the movement of stock prices shows that this isn't always true — and the existence of technical signals like oversold or undersold confirms that fact.

5 Oversold Stocks to Buy Right Now

WILMINGTON, Del.--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial clinical activity in a large cohort of patients with HER2-positive metastatic breast cancer who have brain metastases and received no more than two prior lines of therapy in the metastatic setting. Results will be presented today as a late-breaking presentation (abstract #LBA18) at the European Society f.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases

Biopharmaceutical stock AstraZeneca PLC (NASDAQ:AZN) is 1.3% lower before the open, after a bear note from Deutsche Bank.

AstraZeneca Stock Downgraded on Drug Trial Results

TAMPA, Fla.--(BUSINESS WIRE)--Moffitt Cancer Center announces today a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell (CAR T) and T cell receptor (TCR T) therapies. Under this collaboration, AstraZeneca will have priority access to Moffitt's leading clinical environment and forge strong connections between physician-scientists to accelerate the investigation of novel cell therapies. Advances in cel.

Moffitt Cancer Center Announces Strategic Collaboration with AstraZeneca to Accelerate Oncology Cell Therapies

AstraZeneca saw another £4 billion wiped off its value as top city firm Deutsche Bank cut its recommendation to ‘sell' following the latest update on lung cancer drug datopotamab. Deutsche Bank said it had already reduced its expectations for the drug, but the recent update on biomarker data confirmed its fears and raised new ones.

AstraZeneca hit by sell recommendation after cancer drug update

AstraZeneca's Dato-DXd showed disappointing overall survival data in the TROPION-Lung01 phase 3 trial. Dato-DXd's progression-free survival benefit, especially in biomarker-positive patients, and the totality of the data, support its potential approval despite underwhelming overall survival results. AstraZeneca has many additional shots on goal with Dato-DXd across first and second line+ lung cancer and breast cancer.

AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data

First patient enrolled in Phase 2a study arm combining BI-1206 with rituximab and acalabrutinibwith initial data expected YE 2024 Clinical supply agreement for acalabrutinib with AstraZeneca in place LUND, SE / ACCESSWIRE / September 12, 2024 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has enrolled the first patient in the triple combination arm of the Phase 1/2a study of its anti-FcgRIIB antibody, BI-1206 in non-Hodgkin's lymphoma (NHL). The Phase 2a study arm will combine the subcutaneous formulation of BI-1206 and rituximab with Calquence® (acalabrutinib), a selective inhibitor of Bruton's tyrosine kinase (BTK).

BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence(R) for the Treatment of non-Hodgkin's Lymphoma

A Phase 3 trial found AstraZeneca's (AZN) experimental lung cancer drug datopotamab deruxtecan (Dato-DXd) did not significantly improve patients' overall survival rates.

AstraZeneca Faces Setback From Lung Cancer Drug's Disappointing Trial Results

Sophia Genetics SA

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland , Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023.

SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

Shares in AstraZeneca PLC (LSE:AZN) were the biggest drag on the FTSE 100 on Tuesday, falling over 4.5% on the back of some disappointing results from a trial of a lung cancer drug. Late-stage trial results of the TROPION-Lung01 showed that the overall survival rate from the new drug “did not reach statistical significance,” the company said.

AstraZeneca falls as cancer drug disappoints, analysts cuts FDA approval chances

AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.

AstraZeneca shares fall 5% on disappointing lung cancer drug trial results

London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve overall survival results for patients.

AstraZeneca shares drop as lung cancer drug trial fails to improve survival

Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients in the trial.

AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival

Innate Pharma SA

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented interim results from the randomized NeoCOAST-2 (NCT05061550) Phase 2 platform study during the 2024 World Conference on Lung Cancer on September 8, 2024. The NeoCOAST-2 platform study is intended to assess the safety and efficacy of neoadjuvant durvalumab alone or combined with novel agents and chem.

Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024

Chewy

Chipotle

AstraZeneca's robust pipeline and plentiful growth opportunities make it one of the best healthcare stocks to buy. Chewy is coming off a solid quarter, and there's still more growth ahead in the pet food industry.

News for AstraZeneca Stock (AZN)